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KLF11Farnesoid X Receptor plays an important role in maintaining bile acid, cholesterol homeostasis and glucose
metabolism. Here we investigated whether FXR is expressed by pancreatic β-cells and regulates insulin
signaling in pancreatic β-cell line and human islets. We found that FXR activation induces positive regulatory
effects on glucose-induced insulin transcription and secretion by genomic and non-genomic activities.
Genomic effects of FXR activation relay on the induction of the glucose regulated transcription factor KLF11.
Indeed, results from silencing experiments of KLF11 demonstrate that this transcription factor is essential for
FXR activity on glucose-induced insulin gene transcription. In addition FXR regulates insulin secretion by
non-genomic effects. Thus, activation of FXR in βTC6 cells increases Akt phosphorylation and translocation of
the glucose transporter GLUT2 at plasma membrane, increasing the glucose uptake by these cells. In vivo
experiments on Non Obese Diabetic (NOD) mice demonstrated that FXR activation delays development of
signs of diabetes, hyperglycemia and glycosuria, by enhancing insulin secretion and by stimulating glucose
uptake by the liver. These data established that an FXR-KLF11 regulated pathway has an essential role in the
regulation of insulin transcription and secretion induced by glucose.ental and Clinical Medicine
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Insulin is secreted uniquely from the islet β-cells of the pancreas
and plays a non dispensable role in the maintenance of glucose and
energy homeostasis. Insulin secretion is tightly regulated to maintain
blood glucose levels within a narrow physiological range and an
insufﬁcient secretion of insulin from β-cells contributes to the chronic
hyperglycemia characteristic of diabetes [1]. Glucose is the major
nutrient regulator of pancreatic β-cell function and coordinately
regulates insulin gene expression, insulin biosynthesis and secretion
[1]. A highly conserved region lying ~350 bp immediately upstream of
the transcription initiation start, referred to as the insulin promoter,
confers both tissue-speciﬁc expression and metabolic regulation of
the insulin gene [2,3]. Several transcription factors: PDX1, MafA,
BETA2, E47 and KLF11 act on this region, generating a highly so-
phisticated transcriptional network that ensures precise regulation of
insulin release [4–8]. Glucose controls all steps of insulin gene
expression, including transcription, pre-RNA splicing, and mRNA
stability. Thus, glucose promotes the binding of PDX-1 and KLF11transcription factors to the insulin promoter and the recruitment of
co-activators, such as p300, that modulate chromatin structure
through post-translational modiﬁcations of histones such as methyl-
ation and/or acetylation [9–11]. In addition to its major effects on the
rate of insulin gene transcription, glucose stabilizes pre-proinsulin
mRNA through the direct binding to pyrimidine-rich sequence located
in the 3′-untranslated region of the insulin mRNA [12–14].
The Farnesoid X Receptor (FXR) is a member of the nuclear
receptor superfamily of ligand regulated receptors that function as a
bile acid sensor [15–17]. A major physiological role of FXR is the
regulation of the conversion of cholesterol into bile acids. FXR protects
liver cells from bile acid overload by decreasing their uptake, endog-
enous production and by accelerating their biotransformation and
excretion [18,19]. The generation and phenotype characterization of
FXR-deﬁcient (FXR−/−) mice has allowed to establish that FXR has an
important role in lipidmetabolism and glucose homeostasis. Thus, not
only do FXR−/− mice display elevated serum levels of free fatty acids
(FFAs), triglycerides and high density lipoprotein cholesterol (HDL-C)
[20,21] but also develop signs of insulin resistance as shown by
hyperglycemia, impaired glucose tolerance, and severely blunted
insulin signaling in both liver andmuscle [22,23]. Activation of FXR by
synthetic agonists or hepatic overexpression of constitutively active
FXR by adenovirus-mediated gene transfer reduces blood glucose
levels in obese fa/fa rats, diabetic, leptin deﬁcient, db/db and wild-
type mice. [23,24]. This decrease in plasma glucose levels in db/db
mice was associated with decreased glucose-6-phosphatase expres-
sion, increased glycogen levels and synthesis in the liver providing
Table 1
Primers used for quantitative and qualitative PCR.
Forward Reverse
hGAPDH gaaggtgaaggtcggagt catgggtggaatcatattggaa
hFXR tacatgcgaagaaagtgtcaaga actgtcttcattcacggtctgat
mGAPDH ctgagtatgtcgtggagtctac gttggtggtgcaggatgcattg
mFXR tgtgagggctgcaaaggttt acatccccatctctctgcac
minsulin-1 ggacccacaagtggaacaac gctggtagagggagcaaatg
mGLUT2 ccctgggtactcttcaccaa gccaagtaggatgtgccaat
mGLUT4 gattctgctgcccttctgtc attggacgctctctctccaa
mKLF11 gtcaaagatcccagaaaggt ttgggaagaaacaggtgtcc
NOTE: h=human, m=mouse.
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sensitizing to insulin action [22,23]. Studies on FXR−/− mice seem
also to indicate that the kinetic of insulin release by β-cells could be
altered in the absence of FXR, suggesting that this nuclear receptor
might also directly regulate insulin release [25–28]. Here, we report
that pancreatic β-cells express FXR and that activation of this nuclear
receptor regulates both insulin transcription and secretion induced by
glucose.
2. Material and methods
2.1. Cell culture
Mouse βTC6 cells, an insulinoma cell line, were grow at 37 °C in
Dulbecco's modiﬁed Eagle medium with a low glucose concentration
(ﬁnal: 5 mM) and supplemented with 10% FBS, L-glutamine, penicillin
and streptomycin. Cells were stimulated with 6E-CDCA (1μM) or high
glucose (ﬁnal: 25 mM)orboth.HumanHepG2cells, a hepato-carcinoma
cell line, were grown at 37 °C inMinimum Essential Mediumwith Earl's
salts containing 10% FBS, L-glutamine, penicillin and streptomycin. Cells
were regularly passaged to maintain exponential growth. Human islets
were kindly provided by Dr. Giuseppe Basta, Department of Internal
Medicine, Section of Internal Medicine, Endocrine and Metabolic
Sciences, University of Perugia. The use of human islets was approved
by the Ethics Committee of the University of Perugia (Italy).
2.2. Animals
The animal studies were approved by the Animal Study Committee
of the University of Naples (Italy). Non Obese Diabetic (NODIII) mice
with severe glycemia were housed at the animal facility of the
University of Naples “Federico II”, Naples, Italy. Animals from 14 to
24 weeks of age were administered three times a week by gavage
with 6E-CDCA 5 mg/kg. Control animals, naïve NOD, were adminis-
tered vehicle alone (carboxymethylcellulose 0.2%). Blood glucose
levels and urinary glucose excretion were measured every week,
while plasmatic insulin concentrations have been assessed at the end
of the experimental treatment. Glycemia was monitored by the
Accucheck system (Roche, Milan, Italy), glycosuria was detected with
the Glucose trinder kit 100 (Sigma Chemical Co. Milano, Italy) and
insulin plasmatic levels were assayed by Mercodia insulin ELISA
immunoassay (cat. 10-113-01, Mercodia, Bologna, Italy).
2.3. Insulin release
Insulin release from βTC6 cultures and human islets was assayed
by Mercodia mouse or human insulin ELISA immunoassay (cat. 10-
1150-01 and cat. 10-113-01, respectively).
2.4. Glucose uptake
For this assay, βTC6 cells were cultured on 10 cm2 Petri culture
dishes at the concentration of 2×106 and then starved overnight. Next
day cells were incubated for 2h at 37 °C in glucose uptake buffer
(8.1 mM Na2HPO4, 1.4 mM KH2PO4, 2.6 mM KCl, 136 mM NaCl,
0.5 mM MgCl2, 0.9 mM CaCl2, pH 7.4), stimulated with 1μM of 6E-
CDCA for 45min and subsequently incubated with 1 µCi of [3H]2-
deoxyglucose (New England Nuclear, Boston, MA) in glucose uptake
buffer for 15min at 37 °C. Cells were ﬁnally lysatedwith ice cold 1 mM
NaOHand the radioactivitywasmeasured using a scintillation counter.
2.5. Qualitative PCR
Total RNA was isolated from HepG2, βTC6 and human pancreatic
islets using the TRIzol reagent according to the manufacturer's
speciﬁcations (Invitrogen, Milan, Italy). One μg RNA was puriﬁed ofthe genomic DNA by DNase I treatment (Invitrogen) and random
reverse-transcribed with Superscript II (Invitrogen) in 20μl reaction
volume. The ampliﬁcation of cDNA (50 ng) was achieved in 50 μl
mixture containing 200nM dNTPs, 1.5 mM MgCl2, 200nM of gene
speciﬁc sense and antisense primers and 1U of Platinum Taq DNA
Polymerase (Invitrogen, Milan, Italy). PCR was conducted as follows:
after an initial denaturation at 94 °C for 5min, 35 cycles of am-
pliﬁcation (94 °C for 30s, 58 °C for 15s, and 72 °C for 30s) were
performed followed by 5min of ﬁnal extention at 72 °C. The quality of
RNA samples was evaluated using GAPDH speciﬁc primers. PCR
products were separated by electrophoresis on 2% agarose gel and
stainedwith ethidium bromide. The band of each target transcriptwas
visualized and photographed by ultraviolet transillumination (Bio-
Rad, Gel Doc 2000). All PCR primers were designed with PRIMER3-
OUTPUT software using published sequence data from the NCBI
database (Table 1).2.6. Quantitative real-time PCR
Fifty ng template was added to the PCRmixture (ﬁnal volume 25 µl)
containing the following reagents: 0.2 µM of each primer and 12.5 µl of
2X SYBR Green qPCRmaster mix (Invitrogen, Milan, Italy). All reactions
were performed in triplicate and the thermal cycling conditions were:
2min at 95 °C, followed by 40 cycles of 95 °C for 20s, 55 °C for 20s and
72 °C for 30s in iCycler iQ instrument (Bio-Rad, Hercules, CA). Themean
value of the replicates for each sample was calculated and expressed as
cycle threshold (CT: cycle number at which each PCR reaction reaches a
predetermined ﬂuorescence threshold, set within the linear range of all
reactions). The amount of gene expression was then calculated as the
difference (ΔCT) between the CT value of the sample for the target gene
and the mean CT value of that sample for the endogenous control
(GAPDH). Relative expression was calculated as the difference (ΔΔCT)
between theΔCT valuesof the test sample andof the control sample (not
treated) for each target gene. The relative quantitation value was
expressed and shown as 2−ΔΔCT. All PCR primers were designed with
PRIMER3-OUTPUT software using published sequence data from the
NCBI database (Table 1).2.7. Western blotting anti-FXR
Cell cultures of HepG2 and βTC6 and in vivo isolated human
pancreatic islets were lysated in NuPAGE sample buffer 1X (Invitrogen)
containing Sample Reducing agent (Invitrogen) and 2×105 cells were
separated by polyacrylamide gel electrophoresis (PAGE). The proteins
were then transferred to nitrocellulose membrane (Bio-Rad) and
probed with primary antibodies FXR (Santa Cruz H-130) and tubulin
(Sigma). The anti-immunoglobulin G horseradish peroxidase conjugate
(Bio-Rad) was used as the secondary antibody and speciﬁc protein
bands were visualized using Super SignalWest Dura (Pierce, Euroclone,
Milan, Italy), following the manufacturer's suggested protocol.
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Cell cultures of βTC6 were serum starved for 24h and then
incubated for 0, 5, 15, 30 and 60min with 1μM 6E-CDCA. Total
lysates were prepared by solubilization of cells in E1A lysis buffer
(250 mM NaCl, 50 mM hepes pH 7, 0.1% NP40, 5 mM EDTA)
containing both protease and phosphatase inhibitors (Roche) and
separated by polyacrylamide gel electrophoresis (PAGE). The
proteins were then transferred to nitrocellulose membrane (Bio-
Rad) and probed with primary antibodies phospho-Akt (threonin
308) and total Akt (Cell Signaling, Milan, Italy). The anti-
immunoglobulin G horseradish peroxidase conjugate (Bio-Rad)
was used as the secondary antibody and speciﬁc protein bands
were visualized using Super Signal West Dura (Pierce), following
the manufacturer's suggested protocol.2.9. Immunocytochemistry analysis
Immunocytochemistry analysis of FXR was performed in βTC6,
human islets and HepG2. Brieﬂy, cells were ﬁxed in acetone 95% for
5min and endogenous peroxidase were blocked using Dako Peroxide
Blocking (DAKO) for 10min. Antibody anti-FXR purchased from Santa
Cruz Biotechnology was used at a dilution of 1:50 for 1h at room
temperature and biotin–streptavidin-HRP detection system was used
using DAB substrate chromogen.Fig. 1. Farnesoid X Receptor is expressed in human islets and in βTC6 cell line. Quantitative r
analysis (original magniﬁcation 40×) (D), showing FXR expression in human islets and βTC2.10. Design and transfection of FXR and KLF11 siRNA
Synthetic and validatedpre-designed siRNA formouse FXR andKLF11
were synthesized and puriﬁed by Dharmacon Research, Inc (Dallas, TX).
Transfections of siRNA (at 13nM) were performed in βTC6 in the
presence of high glucose concentrations using the Transit TKO Transfec-
tion reagent (Mirus, Madison, WI). 48h post transfection cells were
stimulatedwith 1 µM6E-CDCA for 18h and then lysated inTrizol Reagent
(Invitrogen) toextractRNAand to check theexpressionof FXR,KLF11and
insulinbyquantitative real-timePCR.Cellular supernatant fromβTC6was
used to test the quantity of insulin released in the culture medium.
2.11. Immunoﬂuorescence assay
Immunoﬂuorescence analysis of glucose transporter GLUT2 was
performed inβTC6 cells. After treatmentwith 1μM6E-CDCA for 60min
cells were washed with ice-cold PBS, ﬁxed with 4% paraformaldehyde
in PBS for 10min on ice and then permeabilized with 0.2% Tween-20/
PBS for 15min. After washing, cells were stained with primary
antibody GLUT2 (Santa Cruz) at a dilution of 1:50 in PBS followed by
FITC-conjugated goat anti-Rabbit IgG (Invitrogen) incubation. Nuclei
were stainedwith DAPI. The imageswere acquiredwith a ﬂuorescence
microscope (Olympus) using the ProgResC14 camera and the IAS 2000
image software (Delta Sistemi, Rome, Italy). Negative controls
included the omission of the primary or secondary antibody. No
staining was observed under the negative control conditions.eal-time PCR (A), Qualitative PCR (B), Western blotting (C) and Immunocytochemistry
6 cell line.
Fig. 2. Farnesoid X Receptor function on glucose-induced insulin secretion and transcription. βTC6 cells were incubated 18h with 6E-CDCA 1 μM in conditions of low and high
glucose (5 mM or 25 mM). Insulin secretion (A), insulin-1 mRNA expression (C) and FXR mRNA expression (D) were measured. Human pancreatic islets were incubated with 6E-
CDCA 1 μM in conditions of high glucose (25 mM) and insulin release was measured (B). Values are mean±S.D. of 3 experiments. *pb0.05 versus high glucose not stimulated cells.
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All values are expressed as mean±S.D. of n values per group.
Comparisons of more than two groups were made with a one-
way ANOVA with post-hoc Tukey's test. Comparison of two
groups was made using Student's t-test for unpaired data when
appropriate. Differences were considered statistically signiﬁcant
if p was b0.05.Fig. 3. siRNA targeting FXR reduces both insulin secretion and transcription. βTC6 cells were
with 6E-CDCA 1μM for 18h in the presence of 25 mM glucose. Quantitative PCR of insulin-1 m
Values are mean±S.D. of 3 experiments. *pb0.05 versus wild-type cells. #pb0.05 versus w3. Results
3.1. FXR is expressed in human islets and in βTC6
We ﬁrst investigatedwhether human islets and βTC6 cells express a
functionally active FXR [30]. As illustrated in Fig. 1, the FXR mRNA was
detected inprimary cultures of human islets and inβTC6byquantitative
(Fig. 1A) and qualitative PCR (Fig. 1B). In these experiments HepG2 cellstransiently transfected with a small interfering RNA targeting FXR and then stimulated
RNA expression (A), FXR mRNA expression (B) and insulin release (C) were measured.
ild-type stimulated cells.
367B. Renga et al. / Biochimica et Biophysica Acta 1802 (2010) 363–372were used as a positive control. FXRmRNAmeasured by qualitative PCR
was found as a 148 bp band in either HepG2 or human islets, while in
murine βTC6 cells FXR mRNA was detected as a 153 bp band. FXR
protein (≈55 kDa) was detected by Western blot analysis in HepG2,
βTC6 cells and, although at lower levels, in human islets (Fig. 1C). In
human islets, the FXR antibody recognizes two bands likely represen-
tative of two FXR isoforms. By immunocytochemistry analysis expres-
sion of FXR (Fig. 1D)was foundpredominantly in thenucleuswithweak
staining throughout the cytoplasm.
3.2. FXR regulates glucose-induced insulin secretion and transcription
To investigate the functional role of FXR in pancreatic β-cells,
βTC6 and human islets were incubated 18hwith the synthetic ligandFig. 4. FXR regulated GLUT2 translocation, glucose uptake and induced Akt phosphorylation
glucose and quantitative PCR of GLUT2 mRNA expression was performed. Values are mean±
the presence of 25 mM glucose and GLUT2 translocation at plasma membrane was observ
stimulated with 6E-CDCA 1μM for 0, 5, 15, 30 and 60min in the presence of 25 mM glucose.
Western blot analysis and quantitation performedwith Image J software. (D) βTC6 cells were
uptake was assayed. Values are mean±S.D. of 10 experiments. *pb0.05 versus not stimula6E-CDCA at 1 μM in conditions of low and high glucose (5 or 25 mM).
As shown in Fig. 2, 6E-CDCA increases the release of insulin in both
βTC6 and human islets exposed to 25 mM glucose but not in βTC6
cells incubated with low glucose concentrations (Figs. 2A and B,
n=3; *pb0.05). Similarly, βTC6 exposed to high glucose and 6E-
CDCA showed a 20 fold increase in the expression of insulin-1 mRNA
in comparison to cells exposed to high glucose only (Fig. 2C, n=3;
*pb0.05). We have also assessed the relative mRNA expression of
FXR in cells exposed to the FXR ligand and found that receptor
ligation caused a robust induction of the FXR gene expression. Again
this effect was documented only in βTC6 cells exposed to high
glucose (Fig. 2D, n=3; *pb0.05). In aggregate, these data suggest
that FXR plays a role in regulating insulin release and transcription
induced by high glucose.. (A) βTC6 cells were stimulated with 6E-CDCA 1μM for 18h in the presence of 25 mM
S.D. of 3 experiments. (B) βTC6 cells were stimulated with 6E-CDCA 1μM for 60min in
ed by Immunoﬂuorescence analysis. Original magniﬁcation 40×. (C) βTC6 cells were
Akt phosphorylation on threonin 308 and total Akt protein expression was analyzed by
stimulatedwith 6E-CDCA 1μM for 60min in the presence of 25 mMglucose and glucose
ted cells.
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insulin release and insulin mRNA expression in βTC6 cells
To test whether FXR directly regulates the synthesis and release of
insulin, a small interfering RNA targeting FXR was transfected into
βTC6 stimulated with or without 6E-CDCA, 1μM for 18h, in the
presence of 25 mM glucose. As illustrated in Fig. 3, transfection of
βTC6 with an FXR siRNA resulted in a profound downregulation of
FXR gene expression as well as in a downregulation of insulin-1mRNA
(Figs. 3A and B, n=3; *pb0.05 versus wild-type cells; #pb0.05 versus
wild-type stimulated cells). In addition, insulin transcription and
secretion failed to respond to stimulation by 6E-CDCA in cells
transfected with the FXR siRNA, further conﬁrming the speciﬁcity of
this synthetic ligand (Figs. 3A and C, n=3; *pb0.05 versus wild-type
cells; #pb0.05 versus wild-type stimulated cells).
3.4. FXR regulates GLUT2 translocation, glucose uptake and Akt
phosphorylation in βTC6 cells
We have then investigated whether FXR modulates GLUT2 ex-
pression and activity in βTC6. The results of these experiments
demonstrated that while FXR activation has no effect on GLUT2 gene
expression (Fig. 4A) it induced a rapid translocation of the transporter
to the plasma membrane (Fig. 4B). In addition, protein phosphoryla-
tion studies clearly demonstrated that FXR activation caused a rapid
phosphorylation of Akt in threonin 308. The kinetic of this effect was
consistent with the kinetic of the GLUT2 relocation to the plasma
membrane, as the Akt phosphorylation peaked at 5–15min, declined
at 30min and was not detected after 60min of incubation (Fig. 4C and
Image J quantitation). Consistent with these ﬁndings, exposure to 6E-
CDCA directly stimulated glucose uptake by βTC6 cells (Fig. 4D,
n=10; *pb0.05). All together these data established that an FXR-
dependent induction of Akt signaling cascade leads to GLUT2
relocation at plasmamembrane rafts and increases the glucose uptake.
3.5. FXR induces KLF11 transcription factor
Since KLF11 is a glucose-inducible regulator of the insulin gene, we
have investigated whether FXR modulates the expression of this
transcription factor in βTC6 cells. For this purpose, cells were
incubated 18h with 6E-CDCA 1 μM, in conditions of low and high
glucose (5 and 25 mM). Results from these experiments demonstrate
that KLF11 mRNA expression was robustly induced by high glucose
concentrations (Fig. 5, columns 1 and 3, n=3; *pb0.05 versus lowFig. 5. FXR activation induces glucose-inducible regulator KLF11 transcription factor.
βTC6 cells were incubated with 6E-CDCA in conditions of low glucose (5 mM) and high
glucose (25 mM) for 18h and relative mRNA expression of KLF11 was measured by
quantitative PCR. Values are mean±S.D. of 3 experiments. *pb0.05 versus low glucose
alone; #pb0.05 versus high glucose alone.glucose alone). This effect was ampliﬁed by FXR activation in
condition of both low and high glucose (Fig. 5, n=3; *pb0.05 versus
low glucose alone; #pb0.05 versus high glucose alone).
3.6. Small interfering RNA targeting KLF11 reduces both insulin release
and expression by βTC6
To investigate the role of KLF11 in mediating insulin gene
transcription and secretion in response to FXR, βTC6 cells were
transiently transfected with a siRNA for KLF11 and then stimulated
with 6E-CDCA, 1μM for 18h, in the presence of high glucose. As shown
in Fig. 6, KLF11 silencing strongly downregulated the relative mRNA
expression of insulin-1 as well as the insulin secretion. In this
experimental setting exposure to 6E-CDCA failed to stimulate insulin
secretion induced by glucose (Figs. 6A and B, n=3; *pb0.05 versus
wild-type cells; #pb0.05 versus wild-type stimulated cells). Thus,
KLF11 is required for regulation of insulin transcription and secretion
by FXR.
3.7. Activation of FXR stimulates insulin secretion in vivo
To elucidate the physiological role of FXR in insulin secretion in
vivo, we have investigated the effect of administering NOD mice with
an orally active FXR agonist (6E-CDCA 5 mg/kg three times a week
from 14 to 24 weeks). As shown in Figs. 7A and B, treating NOD mice
with 6E-CDCA lowered glycosuria and glycemia during all period
treatment signiﬁcantly delaying the onset of diabetes (Figs. 7A and B,
n=6; *pb0.05 versus naïve NOD mice). Assessment of glucose and
insulin plasma levels at 24 weeks demonstrated that, despite FXR
activation caused a robust reduction of glucose plasma levels, it
caused a slight, non signiﬁcant, increase in absolute insulin plasma
levels (Figs. 7C and D, n=6; *pb0.05 versus naïve NOD mice). Of
relevance, however the ratio of insulin plasma levels to glucose
plasma levels was approximately six fold higher in mice administered
6E-CDCA than in the control group (Fig. 7E, n=6; *pb0.05 versus
naïve NOD mice). This effect was not linked to a prevention of β-cells
destruction since pancreatic content of insulin-1, GLUT2 and FXR
mRNA was essentially the same, thought that FXR activation caused a
slight, but signiﬁcant, increase of pancreatic insulin-1 mRNA (Figs. 8A,
B and C, n=3; *pb0.05 versus naïve NOD mice). In addition to these
pancreatic effects, FXR activation enhanced GLUT4 mRNA expression
in the liver suggesting a potential effect of the ligand in the liver
insulin signaling pathway (Figs. 8D and E, n=3; *pb0.05 versus naïve
NOD mice).
4. Discussion
Pancreatic β-cell contains a range of nuclear receptors implicated
in the regulation of insulin secretion [30]. As an example, LXRβ
activation in β-cells increases insulin secretion along with genes
regulatingβ-cell differentiation [31–34].Moreover, glucose stimulates
LXR transcriptional activity in the liver and induces nuclear localiza-
tion and activation of LXR in β-cells [35,36]. Similarly, peroxisome
proliferator-activated receptor (PPAR) isoformsα and γ are expressed
in pancreatic islets aswell as in insulin-producing cell lines and ligands
for PPARγ enhance glucose-induced insulin secretion in rat pancreatic
cells [37–41].Many of these effects aremediated by the transcriptional
modulation of glucose transporters (GLUT1, 2, 3, and 4), a family of
membrane proteins that transport glucose along a gradient concen-
tration [42,43]. GLUT2 is the main glucose transporter expressed by
pancreatic β-cells [43]. Substantial data support the notion that
activation of the PI3-kinase (PI3K) by glucose and subsequent
phosphorylation of Akt are essential steps for the stimulation of the
translocation of glucose transporters at plasma membrane [44,45],
thus regulating its own uptake. Furthermore, glucose coordinately
recruits a highly sophisticated network of transcription factors and co-
Fig. 6. 6E-CDCA failed to regulate insulin release and expression in cells transfected with a siRNA targeting KLF11. βTC6 cells were transiently transfected with a small interfering RNA
targeting KLF11 and then stimulated with 6E-CDCA 1μM for 18h in the presence of 25 mM glucose. Quantitative PCR of insulin-1 mRNA expression (A) and insulin release (B) were
measured. Values shown are mean±S.D. of 3 experiments. *pb0.05 versus wild-type cells. #pb0.05 versus wild-type stimulated cells.
Fig. 7. FXR activation stimulates insulin secretion in vivo. Non Obese Diabetic (NOD) mice were treated three times a week with 6E-CDCA 5 mg/kg by gavage from 14 to 24 weeks.
(A) Time course of glycosuria. (B) Time course of glycemia. (C) Blood glucose and (D) plasma insulin levels after 24 weeks. (E) Ratio of the plasma insulin level to blood glucose level
after 24 weeks. Values are mean±S.D. of 6 experiments. *pb0.05 versus naïve NOD mice.
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Fig. 8. FXR stimulates insulin gene in vivo. Non Obese Diabetic (NOD) mice were treated from 12 to 24 weeks with 6E-CDCA 5 mg/kg by gavage three times a week. Quantitative PCR
of (A) pancreatic insulin-1, (B) pancreatic GLUT2, (C) pancreatic FXR, (D) liver GLUT4 and (E) liver FXR mRNA expressions. Values are mean±S.D. of 3 experiments. *pb0.05 versus
naïve NOD mice.
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mRNA [3]. The repertoire of insulin gene transcription factors activated
by glucose includes KLF11. In pancreatic β-cell KLF11 is regulated by
TGF-β, a pathway playing a critical role in the development and
homeostasis of both the exocrine and endocrine pancreas. In addition,
KLF11 regulates genes encoding for scavengers of oxidative stress,
such as SOD2 and catalase 1 [8,47]. Sequencing of the KLF11 gene in
families enriched for early onset of type 2 diabetes has uncovered two
missense mutations (A347S and T220M) which segregated with
diabetes. Other sequencing efforts have led to identiﬁcation of 19
commonpolymorphisms several of whichwere associatedwith type 2
diabetes in an initial case-control study totaling 626 French indivi-
duals. Further genotyping studies have only partially replicated these
data [8,47]. In light of these evidences, it has been speculated that
KLF11 could be a target for the therapy in a subset of diabetic patients
[8].
In this study we have shown that FXR regulates insulin tran-
scription and secretion by genomic and non-genomic effects. Our in
vitro results indicate that genomic effects of FXR activation on insulin
lead to induction of insulin gene expression. Regulation of insulin
mRNA expression by FXR is glucose dependent and requires induction
of the transcription factor KLF11. We have shown that KLF11 is an
essential modulator for the FXR activity on insulin gene expression
and results from KLF11 silencing experiments have shown that FXR
activation failed to regulate the transcription of the insulin gene in the
absence of KLF11. Supporting this view, feeding NOD mice with an
FXR agonist signiﬁcantly increased insulin-1 gene expression in the
pancreas. Despite the mechanistic relevance of KLF11 in regulating
insulin secretion induced by FXR, we have been unable to ﬁnd an
FXR responsive element in promoter of this transcription factor,
suggesting that regulation of KLF11 gene expression by FXR is due to anon-genomic effect. In aggregate, these results demonstrate that FXR
acts by a KLF11 mediated pathway responsible for the ability of this
nuclear receptor to modulate the glucose-induced insulin gene tran-
scription and provide evidence that FXR could be considered a new
activator of this transcription factor.
In addition FXR regulates insulin secretion by non-genomic effects.
Thus, FXR increases Akt phosphorylation induced by glucose favour-
ing the Akt-dependent translocation of GLUT2 to plasma membrane.
Because this event results in an increased glucose uptake by
pancreatic β-cells these pathways might also contribute to insulin
secretion. Support of this concept comes from the results of FXR
silencing experiments demonstrating that insulin release triggered by
high glucose was signiﬁcantly reduced by FXR gene ablation.
The effects of FXR activation on insulin secretion and transcription
were observed only at high glucose, but the regulation of KLF11mRNA
was observed both at low and high glucose. Despite the fact that
results shown in Fig. 6A demonstrates that KLF11 is essential for
insulin release induced by FXR in condition of high glucose, these
ﬁndings seems to establish a hierarchy among different regulatory
mediators in insulin secretion. Thus, activation of KLF11 per se is
unable to promote insulin secretion and transcription in condition of
low glucose. This is likely related to the fact that exposure to high
glucose recruits a number of regulatory factors to the insulin
promoter (PDX1, MAF-A, etc) [4–8] that are not recruited in condition
of low glucose.
An important observation made in this study was that in vivo
activation of FXR delays the onset of autoimmune type I diabetes in
NOD mice. Compared with other animal models of diabetes
characterized by high levels of plasmatic insulin (fa/fa rats, db/db
and ob/ob mice) NOD mice develop an insulin-dependent diabetes
that is characterized in its ﬁrst stage by a defective insulin secretion
371B. Renga et al. / Biochimica et Biophysica Acta 1802 (2010) 363–372related to an impaired insulin signaling [48–50]. This is followed by a
second stage of islets destruction, insulitis and leukocytic inﬁltration
of the pancreatic islets, characterized by polydipsia, weight loss,
glycosuria and persistent hyperglycemia [48–50]. This second phase
has been partially ascribed to increased production of inﬂammatory
mediators such as TNFα, IL1β and IFNγ in the pancreas [41–52].
Despite the NOD model is characterized by progressive insulin
deﬁciency, we felt that this could have been an important model to
examine the effect of FXR on regulation of insulin signaling in
pancreatic β cells. Indeed, because FXR might function by increasing
peripheral insulin sensitivity [20–24], this insulin-deﬁcient model
appears to be more relevant for the study of central activity of FXR
than other models characterized by peripheral insulin resistance.
Present results demonstrate that blood glucose levels and
glycosuria were signiﬁcantly ameliorated by FXR activation in NOD
mice. Furthermore, FXR activation ameliorated the ratio of plasma
insulin level to blood glucose level, suggesting a stimulation of insulin
secretion in vivo. The ability to modulate insulin release was not
linked to prevention of β-cell destruction by the FXR agonist. Thus,
despite we have not performed a morphometric examination of NOD
pancreatic islets, we observed that not only mRNA expression of
insulin-1, GLUT2 and FXR in pancreatic beta cells of mice adminis-
tered with the FXR ligand were similar to that of naïve NOD mice, but
also absolute plasma insulin levels were similar in both mice groups.
Collectively, these data suggest that the two groups underwent a
similar extent of pancreatic injury excluding that beta-cell protection
ground the mechanism of action described in this paper.
In addition to these effects on pancreatic β-cells, FXR activation
induces the expression of GLUT4 in the liver, conﬁrming previous data
indicating that the GLUT4 promoter contains an FXR responsive
element [29]. Because the liver is an important tissue for glucose
storage into glycogen, induction of GLUT4 and regulation of insulin
receptor sensitivity [24] is also likely to contribute to the metabolic
control we documented in this study and is consistent with previous
reports demonstrating that FXR gene ablation impairs insulin
signaling [20–24].
In summary, we have shown that the bile acid sensor FXR is
expressed by pancreatic β-cells and human islets and regulates the
insulin signaling by genomic and non-genomic effects. Genomic
effects include KLF11 mediated stimulation of insulin gene expres-
sion. Non-genomic effects include an Akt mediated stimulation of
glucose induced relocation of GLUT2 in β-cells. Finally these effects
are reproduced in vivo in a rodent model of insulin-deﬁcient diabetes
developing in NOD mice. The present study provides further support
for the potential role of the FXR agonists in regulation of glucose
homeostasis.References
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